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costs and productivity losses were calculated. Costs data were derived from Russian 
cost-of-illness study of depression and registered maximal drug prices list. The 
outcomes were modelled for 3 years period. Costs were converted to EUROs using 
the average weighted exchange rate in 2014 (1€ = 50.815RUR). Sensitivity analysis 
was performed. Results: Agomelatine appeared to be the dominant therapy in 
comparison with branded fluoxetine, sertraline and escitalopram, which allowed 
achieving maximum clinical outcome and utility (2.148 QALY vs 2.097, 2.133 and 
2.119 QALY, respectively) at the lowest costs (€ 1,932 vs € 2,485, € 2,076 and € 2,454). 
Agomelatine remained dominant strategy even when only direct medical costs 
were included into analysis (€ 943 vs € 1,172, € 1,002 and € 1,290). ConClusions: 
Agomelatine was demonstrated to be the rational choice in comparison with other 
branded antidepressants routinely used in Russian health care settings.
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PriMary Care DeMentia CliniC reDuCes soCietal Cost of DeMentia: a 
Cost-utility analysis
Teo WK
National Healthcare Group, Singapore, Singapore
objeCtives: The prevalence of dementia in Singapore is expected to increase with 
an ageing population. With the inclusion of dementia as part of Chronic Disease 
Management Program, more primary care consultations are expected in the poly-
clinic. A Primary Care Dementia Clinic (PCDC) was set up in Ang Mo Kio Polyclinic to 
manage stable patients. The objective of this study is to evaluate the cost-utility of 
dementia care at PCDC compared with specialists’ care at the Memory Clinic (MC) 
and care at other polyclinics. Methods: Stable dementia patients with a Clinical 
Dementia Rating of 1.0 – 3.0 were recruited for the programme. Costs were measured 
from the societal viewpoint, including both direct and indirect costs. To establish 
cost-utility, EQ-5D was used to calculate QALYs. Cost and utility were measured at 
six-months and one-year. The incremental cost-effectiveness ratio was calculated 
by dividing the difference in costs by the difference in QALYs. Results: A total of 
168 dementia patients were recruited for this study. 55 for the PCDC arm and 113 
from the two comparator groups (MC = 82 & Other Polyclinics = 31). Compared 
with care at the Memory Clinic and standard polyclinic care, PCDC was $2,110 
(vs. MC) and $2,335 (vs. Other Polyclinics) lower respectively at six-months. There 
were no statistical differences in one-year costs and QALYs across both compari-
sons. ConClusions: Our analysis found that dedicated dementia care for stable 
patients at the primary care setting reduces societal cost. Expansion of PCDC could 
greatly reduce societal resources without impacting patients’ quality of life.
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objeCtives: To examine the economic burden and health care utilization for patients 
diagnosed with opioid abuse in the U.S. veteran population. Methods: Patients 
diagnosed with opioid abuse (International Classification of Diseases, 9th Revision, 
Clinical Diagnosis codes 965.0x and 965.8x) were identified using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2007 through September 
30, 2012. The first diagnosis date was designated as the index date. A comparison 
cohort was created including patients without opioid abuse using 1:1 propensity 
score matching to control for age, region, gender, index year and baseline Charlson 
Comorbidity Index score. The index date was chosen randomly for the comparison 
cohort to minimize selection bias. Patients in both cohorts were required to be at least 
age 18 years and have continuous medical and pharmacy benefits 1 year pre- and 
1 year post-index date. Study outcomes including health care costs and utilizations 
were compared between the disease and comparison cohorts based on the matched 
sample. Results: After 1:1 matching, 1,652 patients were included in each cohort, 
and the baseline characteristics were well-balanced. More patients with opioid abuse 
had inpatient stays (92.37% vs. 5.08%, p< 0.0001) and emergency room (ER) (73.85% vs. 
11.38%, p< 0.0001), physician office (96.91% vs. 71.91%, p< 0.0001), outpatient (97.46% vs. 
72.82%, p< 0.0001) and pharmacy visits (89.83% vs. 75.00%, p< 0.0001). Higher all-cause 
health care costs were also observed for patients with opioid abuse, including inpa-
tient ($29,203 vs. $1,394, p< 0.0001), ER ($1,155 vs. $112, p< 0.0001), outpatient ($9,193 
vs. $2,665, p< 0.0001), pharmacy ($1,516 vs. $696, p< 0.0001) and total costs ($39,913 
vs. $4,757, p< 0.0001) than for study subjects without opioid abuse. ConClusions: 
During a period of 12 months, VHA patients diagnosed with opioid abuse reported 
higher health care utilization and costs than their matched controls.
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objeCtives: To determine which economic burden outcomes were assessed in 
studies on mental health disorders published in 2014. Methods: An evidence sur-
veillance process was established based on a systematic search of PubMed, incor-
porating all studies published from 2010 and updated weekly, with a final search on 
1 June 2015. Abstracts identified by the search for costs or resource use outcomes 
in mental health disorders were identified. Articles were included if they reported 
results from a primary research study or economic model. Economic outcomes were 
identified, where possible, from the abstract alone. Results:: The economic burden 
search identified 1,870 articles published in 2014, with 968 meeting the inclusion 
criteria for any disease. Of these, 76 (8%) were in mental health disorders. The most 
commonly researched disorders were drug, tobacco or alcohol abuse (25 articles), 
followed by depression (17), dementia (7) and schizophrenia (8). The USA was the 
most common setting, based on abstract text or author affiliations (31 articles), fol-
(p< 0.001). According to the QLS MCID, 49% of patients receiving AOM were classified 
as responders vs. 42% of patients receiving PP. For the CGI-S assessment, 52% vs. 34% 
were responders for AOM and PP, respectively. In both assessments, AOM was the 
economically dominant therapeutic option over PP. Univariate sensitivity analyses 
confirmed these findings, the main drivers being cost of inpatient and outpatient 
services. ConClusions: AOM was found to provide superior clinical benefits and 
cost savings compared to PP in all analyses, representing good economic value in the 
maintenance treatment of schizophrenia in the UK.
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Cost-effeCtiveness analysis of oPioiD suBstitution treatMent in 
slovenia
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objeCtives: We analyzed cost effectiveness of buprenorphine/naloxone combina-
tion and sustained release (SR) morphine when compared to methadone in patients 
treated for opioid dependence in Slovenia. To compare the expected costs of treatment 
with buprenorphine/naloxone combination and SR morphine, we also performed 
cost-minimization analysis. Methods: We adapted a micro-simulation decision 
model to the real-life conditions in Slovenia by using locally-specific data for main-
tenance treatment costs of buprenorphine/naloxone, SR morphine, and methadone 
with the average dose of treatment set at 10.68 mg/day for buprenorphine/naloxone, 
592 mg/day for SR morphine, and 82 mg/day for methadone. All other direct costs 
were based on COBRA (Cost-Benefit and Risk Appraisal of Substitution Treatment 
in Routine) study and adjusted to conditions of the local jurisdiction. Clinical effi-
cacy data for all three treatment options were derived from published literature; in 
cost-minimization analysis, we assumed that buprenorphine/naloxone combination 
and SR morphine were clinically equivalent. Main outcome measures were costs, 
gains in quality adjusted life years (QALYs), and incremental cost-effectiveness ratios 
(ICERs). Results: Our model has shown that under the base case scenario, buprenor-
phine/naloxone dominated methadone (by saving € 60 and gaining 0.153 QALY over 
one year); when comparing SR morphine and methadone, the resulting ICER was 
€ 5,434 per QALY. Cost-minimization analysis revealed lower treatment costs with 
buprenorphine/naloxone combination than those with SR morphine by 45% (€ 488 per 
year), with treatment costs of buprenorphine/naloxone and SR morphine accounting 
for 28% and 41% of total direct medical costs, respectively. The sensitivity analysis 
showed robustness of our findings. ConClusions: Results of our study suggest that 
treating patients with buprenorphine/naloxone combination instead of methadone 
or SR morphine appears to be cost-saving in Slovenia. This result is particularly rel-
evant for implementation of treatment guidelines and for those patients who can be 
prescribed as an intervention of choice either buprenorphine/naloxone combination, 
SR morphine or methadone.
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objeCtives: Opioid dependence is a serious and costly medical condition that 
can occur with regular opioid use. We conducted a systematic review of published 
model-based economic evaluations of drug substitution therapy in treating non-
medical opioid dependence. Methods: Literature searches were conducted in 
March 2015 in 8 electronic databases and supplemented by hand-searching refer-
ence lists and searches on 6 health technology assessment (HTA) agency websites. 
The selection criteria included: A population dependent on opioids and receiving 
opioid substitution therapy or maintenance therapy. The intervention included any 
pharmacological maintenance therapy and the comparator included any pharmaco-
logical maintenance regimen, including placebo or no treatment. The outcomes and 
study types included health economic models of any type. Results: After removal 
of duplicates, 2,163 citations were retrieved, of which 63 progressed to full-text 
review. Of these, 19 publications of 18 unique models were included in the review. 
These 18 models used a wide range of modelling approaches, including Markov 
models (n= 4), decision tree with Monte Carlo simulations (n= 4), decision analysis 
(n= 3), dynamic transmission models (n= 3), decision tree (n= 1), cohort simulation 
(n= 1), Bayesian (n= 1), and Monte Carlo simulations for sensitivity analysis (n= 1). 
Time horizons ranged from 6 months to a lifetime. The most common evaluation 
was cost-utility analysis reporting cost per quality-adjusted life-year (n= 11), fol-
lowed by cost-effectiveness analysis (n= 4), budget impact analysis/cost comparison 
(n= 2) and cost-benefit analysis (n= 1). Countries modelled were the US (n= 11), UK 
(n= 4), Spain (n= 1), Vietnam (n= 1) and New Zealand (n= 1). A range of perspectives 
were modelled, including societal and healthcare systems. ConClusions: This 
review identified 8 different modelling structures with a range of perspectives, 
time horizons and inputs, illustrating that there is no single preferred approach. 
Further research is needed into the advantages and disadvantages of the different 
modelling approaches in this disease area.
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tHe Cost effeCtiveness of agoMelatine in tHe treatMent of Major 
DePressive DisorDer
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objeCtives: To evaluate the cost effectiveness of agomelatine versus branded 
fluoxetine, sertraline and escitalopram for treatment of major depressive disor-
ders in adults in Russia. Methods: We have adapted published Markov model 
of major depression disorder. It consisted of 4 different health states (depression, 
remission, well-being and death). Cycle length was 4 weeks. Transition probabili-
ties and utilities were taken from the international published research data. Direct 
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Functioning can be defined as the ability to perform daily activities, and to main-
tain interpersonal relationships and work capacity/productivity. Major Depressive 
Disorder (MDD) is associated with substantial impairment in functioning. The 
study examined associations between various measures of functioning (patient 
assessment) and MDD symptoms (clinician assessment). A major challenge was 
to ensure MDD patient compliance with regular self-assessments and retention in 
a long-term study.objeCtives: The purpose of the Direct to Patient Contact (DPC) 
approach was to maximize patient compliance to Patient Reported Outcomes 
(PRO) data collection and retention in a study conducted in real life settings over 
a two-year follow-up period. Methods: This was an international, multicentric, 
observational, prospective longitudinal cohort study involving 1,500 MDD patients 
followed-up for two years in five European countries. Patients were recruited by 
General Practitioners or psychiatrists and data collected using a hybrid method: 
clinical data by physicians and PRO data self-assessment by patients. DPC actions 
included PRO questionnaire shipments to patients at five time points, followed 
by phone reminder contacts for non-returned questionnaires. Results: 1,450 
patients were included in the study, 97.8% of whom agreed to be contacted directly 
by DPC staff. Overall, 71.7% of patients were reached by phone and 75.6% of PRO 
questionnaires were returned; the questionnaire completion rate reached 95.3%. 
79.6% of patients remained until study end, 0.1% died, 3.5% voluntarily with-
drew from the study and 16.7% were withdrawn for other reasons. There were 
no patients lost to follow up. ConClusions: This study demonstrates that the 
use of DPC in a MDD population, likely to be study non-compliant/unresponsive, 
produced excellent long-term response rates. It minimized voluntary patient 
drop-outs and lost to follow up rates, and ensured an enhanced data collection of 
self-assessed PROs, thus improved reliability of study outcomes.
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objeCtives: Excess chin and neck fat adversely affects facial appearance, producing 
measureable negative impacts on psychological health and psychosocial function. 
The Patient-Reported Submental Fat Impact Scale (PR-SMFIS) is a patient-reported 
outcome (PRO) measure developed and validated to assess submental fat (SMF)-
associated psychological impact and its improvement associated with the reduction 
of SMF with deoxycholic acid (DCA) injection (ATX-101) as an injectable treatment 
for SMF. Methods: Scale development and validation followed global regulatory 
guidelines and industry best practices. A conceptual model and draft response 
items were developed based on literature review, key opinion leader interviews, and 
patient concept elicitation interviews. The resulting 6-item scale assesses negative 
psychological impact of SMF on emotional perceptions (happiness, self-conscious-
ness, bothersomeness, and embarrassment) and visual perceptions (looking older 
and overweight). Items are rated on an 11-point scale (0 = no impact, 10 = extreme 
negative impact); the total scale score is the average response. Six clinical trials of 
ATX-101 for SMF treatment provide assessments of reliability, construct validity, 
sensitivity to change, and score interpretation. PR-SMFIS validity was assessed using 
two generic measures of psychological impact, the Derriford Appearance Scale-24 
(DAS-24) and Body Image Quality of Life Inventory (BIQLI). Results: The PR-SMFIS 
demonstrated high test-retest reliability (Intra-class correlation = 0.75), internal 
consistency (Cronbach’s alpha › 0.92), external validity against the DAS-24 (r = 0.57) 
and BIQLI (r = -0.3), and patient SMF ratings (r = 0.49 to 0.75). SMF treatment pro-
duced large effect sizes (Cohen ES = -2) consistent with effect sizes for clinician and 
patient ratings, and objective measures of SMF reduction. ConClusions: These 
results confirm that PR-SMFIS is a content-valid PRO instrument with robust reli-
ability and validity for SMF psychological impact assessment.
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HuManistiC BurDen in DeMentia: WHiCH tools Were Most CoMMonly 
useD in stuDies PuBlisHeD in PuBMeD in 2014?
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objeCtives: To determine which patient-reported outcome (PRO) and car-
egiver quality of life tools were used in studies on dementia published in 
2014. Methods: An evidence surveillance process was established based on a 
systematic search of PubMed, incorporating all studies published from 2010 and 
updated weekly, with a final search on 18 May 2015. Abstracts identified by the 
search that reported humanistic burden outcomes in dementia were identified. 
Articles were included if they reported results or a study protocol from a primary 
research study or were a systematic review. PRO tools were identified, where 
possible, from the abstract alone. Results: Of 1,980 articles published in 2014 
identified by the search for PROs and quality of life, 32 were relevant to patients 
and/or caregivers of adults with dementia, cognitive impairment or memory loss. 
The PRO used was not specified in 17 abstracts, but 19 different PRO or caregiver-
reported instruments were cited in the remaining 15 abstracts. Dementia-specific 
instruments included the Quality of life-Alzheimer’s disease (QoL-AD), used in 6 
studies, and the Alzheimer’s Disease Assessment Scale - Cognition (ADAS-Cog), the 
Five-Cog test, the Metamemory in Adulthood Questionnaire and the Mild Cognitive 
Impairment Questionnaire (MCQ), used in 1 study each. Despite the substantial 
burden on caregivers, only 8 studies reported outcomes related to the humanistic 
burden in this population. Instruments used in caregivers included generic utility 
measures, the QOL-AD, and the Zarit Burden Interview, but were not specified in 
5 abstracts. Utilities were measured in only 3 studies, with Short Form (12 or 36) 
used in all 3 studies and EQ-5D in one. Depression was assessed in 2 studies of 
lowed by the UK (13), the Netherlands (7) and Germany (4). Despite the high societal 
costs associated with mental illness, this was generally under-reported, with just 
26 of the 76 articles reporting indirect social, productivity, informal care or criminal 
justice costs. In comparison, direct costs were evaluated in 48 articles and healthcare 
resource use in 38 articles. Indirect costs were reported in 6 of the 7 studies from 
the Netherlands, compared with 4 of the 13 UK studies and 6 of the 31 USA studies. 
Caregiver burden was assessed in just 3 studies, one each on dementia, autism and 
depression. ConClusions: Recent research on economic burden in mental health 
disorders has focused disproportionately on the management of substance abuse 
and on direct costs or healthcare resource use. Up-to-date data on indirect costs 
from other chronic mental disorders remains sparse.
Mental HealtH – Patient-reported outcomes & Patient Preference studies
PMH33
estiMating tHe iMPaCts of MeDiCation aDHerenCe anD PersistenCe on 
Costs anD HosPitalization: tHe Case of atyPiCal antiPsyCHotiCs
Ni W, Jiang Y
University of Southern California, Los Angeles, CA, USA
objeCtives: Some studies on the effects of adherence and persistence to antipsy-
chotics on healthcare use suggested negative associations between adherence and 
resource utilization, whereas several other studies suggested positive associations 
or no associations. This study aims to estimate the impacts of adherence and per-
sistence to atypical antipsychotics on costs and hospitalization by reducing possible 
endogeneity. Methods: To examine the effects of adherence (proportion of days 
covered) and persistence (time-to-discontinuation) to atypical antipsychotics in 
the first year following the initiation of atypical antipsychotic therapy on costs and 
hospitalization in the second year, we carried out retrospective analysis of 2007-2013 
Humana claims data. Individuals in the databases with a diagnosis of schizophrenia 
or bipolar disorder at any time and had a prescription for non-injectable atypical 
antipsychotics were identified and selected. Instrumental variable (IV) regressions 
using reimbursement rate and mail order as IVs were conducted to correct poten-
tial endogeneity. Results: Being adherent was associated with decreased total 
costs by US$19,497 (p< 0.05), increased medication costs by US$8,194 (p< 0.001), 
decreased medical services costs by US$27,664 (p< 0.001), and reduced hospitaliza-
tion risk by 27% (p< 0.001). Being persistent was associated with decreased indi-
vidual total costs by US$23,927 (p< 0.05), increased medication costs by US$10,278 
(p< 0.001), and decreased medical services costs by US$34,178 (p< 0.001). We could 
not identify significant association between persistence and the risk of hospitaliza-
tion. ConClusions: Good adherence and persistence to atypical antipsychotics 
lead to lower total costs than poor adherence and persistence. Efforts should be 
made to improve adherence and persistence.
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bACkgRound: Adherence to antidepressant treatment is demanded for both 
clinical and economic effectiveness in treated depression. The Lam Employment 
Absence and Productivity Scale (LEAPS) was acquired, re-validated and tested 
in blind randomization with Thai Depression Inventory (TDI). objeCtives: 
To assess effects of antidepressant-based treatment among ambulatory Thai 
depressed patients after 3 months completed adherence to treatment with TDI 
and LEAPS. Methods: Thai depressed patients in public hospital under antide-
pressant-based treatment were follow-up, 50 were completed adherence for 3 
months. The LEAPS and TDI were assessed independently by both psychiatrists 
and hospital pharmacist. Apparent economic impact of treatment was computed 
based on work-absence employed the minimum daily wage-average of workers 
of the region. Results: 107 depressed patients of 26 Men/81 Women, mean(SD) 
age of 41.9(12.0) years, 34(31.8%) had physical illnesses. 25 patients (23.4%) were 
treated by antidepressant only, 82(76.6%) were treated by anti-depressant plus 
other psychotropics. The Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclics 
Antidepressant (TCAs) and others were prescribed at 55(51.4%), 41 (38.3%) 11 
(10.3%). After 3 months follow-up treatment, significant reduction of both TDI 
and LEAPS with mean(SD) score observed from 50 patients with completed adher-
ence to treatment where depressed symptoms score (assessed with TDI) reduced 
from 34.06(13.5) to 15.9(12.9) (p< 0.05) and LEAPS from 18.16(7.3) to 6.9(6.4) (p< 0.05) 
respectively. Both TDI and LEAPS were well correlated (r= 0.84, p< 0.05). During 3 
months treatment period, work absence was reduced from 86% to 36%. Overall eco-
nomic effectiveness of the adherence to treatment among 50 patients treated with 
anti-depressant-based, unless otherwise economic gains in terms of increased 
productivity could be anticipated from 1.4 to 1.7 Mio THB for the complete adher-
ence to treatment group. ConClusions: Completed adherence antidepressant-
based treatment is effective to reduce clinical symptoms of depression with 
reduction of work absence. The LEAPS and TDI are well correlated suggesting 
further evaluation for its benefits in larger depressed working population.
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Pro self-assessMent anD Patient retention in Major DePression 
stuDies: effiCienCy of a DireCt-to-Patient ContaCt aPProaCH
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